Activity of crizotinib in patients with non-small cell lung cancer

Community Oncology

Volumn 7, Issue 10, 2010, Pages 443-

  Abraham, Jame ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANAPLASTIC LYMPHOMA KINASE; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; HYBRID PROTEIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 78649281412     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70422-3     Document Type: Article

References (2)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
2. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF- 02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(18S):3.